新股消息 | 华恒生物(688639.SH)港股IPO获中国证监会备案

智通财经网04-10

智通财经APP获悉，4月10日，中国证监会国际合作司发布《关于安徽华恒生物科技股份有限公司境外发行上市备案通知书》。华恒生物(688639.SH)拟发行不超过3195.93万股境外上市普通股并在香港联合交易所上市。据招股书，作为全球合成生物技术的先行者，华恒生物专注于依托生物制造技术，开展生物基产品的研发、规模化生产和商业化。该公司拥有前沿的研发实力、强大的技术创新能力、成熟的量产能力，致力于将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2626193897?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20260410/20260410164905_55771.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0","is_english":false,"pubTime":"2026-04-10 16:48","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2626193897","market":"us","top_or_hot":-1,"title":"新股消息 | 华恒生物(688639.SH)港股IPO获中国证监会备案","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，4月10日，中国证监会国际合作司发布《关于安徽华恒生物科技股份有限公司境外发行上市备案通知书》。华恒生物(688639.SH)拟发行不超过3195.93万股境外上市普通股并在香港联合交易所上市。据招股书，作为全球合成生物技术的先行者，华恒生物专注于依托生物制造技术，开展生物基产品的研发、规模化生产和商业化。该公司拥有前沿的研发实力、强大的技术创新能力、成熟的量产能力，致力于将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1427074.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股消息 | 华恒生物(688639.SH)港股IPO获中国证监会备案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股消息 | 华恒生物(688639.SH)港股IPO获中国证监会备案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-10 16:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1427074.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，4月10日，中国证监会国际合作司发布《关于安徽华恒生物科技股份有限公司境外发行上市备案通知书》。华恒生物(688639.SH)拟发行不超过3195.93万股境外上市普通股并在香港联合交易所上市。据招股书，作为全球合成生物技术的先行者，华恒生物专注于依托生物制造技术，开展生物基产品的研发、规模化生产和商业化。该公司拥有前沿的研发实力、强大的技术创新能力、成熟的量产能力，致力于将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1427074.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688639","symbol_name":"华恒生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1427074.html","article_id":"2626193897","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20260410/20260410164905_55771.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626193897","pubTimestamp":1775810926,"columns":[{"name":"新股","id":7,"label_key":null}],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"4月10日，中国证监会国际合作司发布《关于安徽华恒生物科技股份有限公司境外发行上市备案通知书》。华恒生物(688639.SH)拟发行不超过3195.93万股境外上市普通股并在香港联合交易所上市。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688639":"华恒生物","BK0229":"化学制品","SPCX":"SPAC and New Issue ETF","VXUS":"国际股票ETF-Vanguard","IPOS":"Renaissance International IPO ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"New Stock News | Huaheng Biotech (688639.SH) Hong Kong IPO was filed by China Securities Regulatory Commission","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688639":1.5,"IPOS":1.5,"VXUS":1.5,"SPCX":1.5},"content_text":"智通财经APP获悉，4月10日，中国证监会国际合作司发布《关于安徽华恒生物科技股份有限公司境外发行上市备案通知书》。华恒生物(688639.SH)拟发行不超过3195.93万股境外上市普通股并在香港联合交易所上市。据招股书，作为全球合成生物技术的先行者，华恒生物专注于依托生物制造技术，开展生物基产品的研发、规模化生产和商业化。该公司拥有前沿的研发实力、强大的技术创新能力、成熟的量产能力，致力于将实验室技术成果转化为绿色、低碳及高性能的生物基产品及解决方案，满足新涌现的应用场景。凭借二十年来在生物制造领域的深耕，该公司在研发、技术和市场上建立了行业领先地位。根据弗若斯特沙利文的资料：该公司是全球通过合成生物技术实现商业化应用产品最全面生物基产品的企业之一;该公司是全球首家实现系列氨基酸(包括L-丙氨酸及L-缬氨酸)厌氧发酵法产业化的企业;及以2024年收入为衡量标准，该公司L-丙氨酸及L-缬氨酸的市场份额分别位居全球第一。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626193897","isCrawlerRequest":true}